Aerovate Therapeutics (NASDAQ:AVTE) reported quarterly losses of $(0.49) per share. This is a 97.94 percent increase over losses of $(23.80) per share from the same period last year.
Related Posts
BMO Capital Maintains Market Perform on Equinix, Raises Price Target to $755
BMO Capital analyst Ari Klein maintains Equinix (NASDAQ:EQIX) with a Market Perform and raises the price target from $740 to $755.
Wells Fargo Maintains Overweight on Hess, Raises Price Target to $135
Wells Fargo analyst Roger Read maintains Hess (NYSE:HES) with a Overweight and raises the price target from $133 to $135.
Morgan Stanley Maintains Overweight on Signature Bank, Lowers Price Target to $244
Morgan Stanley analyst Manan Gosalia maintains Signature Bank (NASDAQ:SBNY) with a Overweight and lowers the price target from $247 to $244.